



The 23rd JFCR-ISCC New Antitumor Agents under Development in the US, Europe and Japan

2018 December 13 (Thu) 13:00 -19:00
December 14 (Fri) 9:00 -18:00

Miraikan

National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Dec. 13 (Thu)

Session 1

13:10 -

Immunotherapy resistance: Primary and acquired resistance mechanisms

Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Analysis and Regulation of Cellular Diversity (4904)"



Hassane M. Zarour *UPMC Hillman Cancer Center*
Therapeutic strategies to reverse tumor-induced T cell dysfunction

Takashi Ishida *Iwate Medical Univ.*
Mogamulizumab sensitivity and resistance; CCR4 mutations

Yoshihiro Ohue *National Cancer Center*
Analysis of immunological resistance to anti-tumor immunity

Session 2

15:10 -

Cutting edge of immuno-oncology research

16:25 -

Poster Flash Talks

17:15 -

Poster Session & Mixer

Andrea Schietinger *MSKCC*
Molecular programs defining T cell dysfunction in tumors

Tadashi Yokosuka *Tokyo Med. Univ.*
Molecular imaging unveils a mechanism of T cell activation regulation by immune checkpoint microclusters

Dec. 14 (Fri)

Session 3

9:00 -

New drugs under clinical or preclinical investigations


11:15 -

Poster Discussion Session

12:30 -

Luncheon Seminar

Supported by  CHUGAI PHARMACEUTICAL CO., LTD.

 A member of the Roche group

Jaap Verweij *Erasmus Univ.*
OMO-1, a novel highly selective MET inhibitor

Janet Franklin *Amgen Inc.*
Blinatumomab, a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3

Daisuke Morishita *Chordia Therapeutics Inc.*
A novel therapeutic agent for relapsed and refractory lymphomas

Takuo Tsukuda *Chugai Pharmaceutical Co., Ltd.*
"Creation of Alectinib, a highly ALK selective inhibitor"
Kinase inhibitors from basics to breakthrough therapy

Session 4

13:45 -

Epigenetic and DNA damage response inhibitors

Ross Levine *MSKCC*
Role of mutations in epigenetic regulators in myeloid transformation

Yves Pommier *NCI, NIH*
DNA damage response inhibitors: PARP, ATR, HDAC inhibitors, and SLFN11: Update and perspective

Special Lecture

15:15 -

Defining a cancer dependency map

Supported by  Bristol-Myers Squibb

William Hahn *Dana-Farber Cancer Institute*

Session 5

16:45 -

CAR-T cell immunotherapy: Current status and future directions

Naoki Hosen *Osaka Univ.*
The activated conformation of integrin $\beta 7$ is a novel multiple myeloma-specific target for CAR T-cell therapy

Koji Tamada *Yamaguchi Univ.*
Prime CAR-T cell technology for treatment of solid cancers

Contact : Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
jfc-r-iscc@ml.jfcr.or.jp

<http://iscc.umin.jp/>

The 23rd JFCR-ISCC is supported by following companies: Bristol-Myers Squibb K.K., Kyowa Hakko Kirin Co., Ltd., Taiho Pharmaceutical Co., Ltd., AbbVie Inc., Astellas Pharma Inc., Biogen Japan Ltd., Celgene K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FUJIFILM Corporation, MSD K.K., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sysmex Corporation, Yakult Honsha Co., Ltd., Zenyaku Kogyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Novartis Pharma K.K.